Litigation Details for Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC (D. Del. 2020)
✉ Email this page to a colleague
Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC (D. Del. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-03-26 |
| Court | District Court, D. Delaware | Date Terminated | 2023-01-30 |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | Plaintiff | Referred To | |
| Parties | FERRING B.V. | ||
| Patents | 9,415,085; 9,579,359 | ||
| Attorneys | Joshua P. Davis | ||
| Firms | Golo LLC | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2021-06-14 | 141 | Order - -Memorandum and Order | of U.S. Patents Nos. 9,579,359 (“the ’359 Patent”), 10,729,739 (“the ’739 Patent”), 9,415,085 (“the ’…the ’081 Patent, the ’999 Patent, U.S. Patent No. 8,828,938 (“the ’938 Patent”), and U.S. Patent No. 10,973,870…359 Patent cl. 1; ’739 Patent cl. 1, 14, 27; ’085 Patent cl. 1; ’398 Patent cl.…claim terms of the ’359 Patent, the ’739 Patent, the ’085 Patent, the ’398 Patent, Case 1:20-cv-00431-MN… The ’359 Patent, ’739 Patent, and ’870 Patent share a first specification, the ’085 Patent and | External link to document |
| 2021-08-13 | 157 | Notice of Service | Objective Evidence of Non-Obviousness of U.S. Patent Nos. 9,415,085 and 10,695,398; (4) Opening Expert Report…F.A.C.S. Regarding Infringement of U.S. Patent Nos. 9,415,085 and 10,695,398; (5) Opening Expert Report…Regarding Objective Evidence of Non-Obviousness of U.S. Patent Nos. 9,579,359, 10,729,739, and 10,973,870; (6)…Shore, M.D., FACS Regarding Infringement of U.S. Patent Nos. 9,579,359, 10,729,739, and 10,973,870; (7)…on Objective Evidence of Non-Obviousness of U.S. Patent Nos. 8,841,081 and 9,877,999, and (8) Opening Expert | External link to document |
| 2021-09-17 | 159 | Notice of Service | F.R.C.S.I., F.A.C.S. Regarding Validity of U.S. Patent Nos. 9,415,085 and 10,695,398, and (4) Rebuttal Expert …. Higano, M.D., FACP Regarding Validity of U.S. Patent Nos. 8,841,081 and 9,877,999; (2) Rebuttal Expert…D. Shore, M.D., FACS Regarding Validity of U.S. Patent Nos. 9,579,359, 10,729,739, and 10,973,870; (3)…2020 30 January 2023 1:20-cv-00431 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
